Abstract：Objective To explore and analyze the application value and safety of leukocyte filtration transfusion technology in clinical blood transfusion.Methods From June 2018 to May 2020, 80 blood transfusion patients admitted to Baicheng Hospital of Jilin Province were selected as the research objects, and they were divided into the observation group (40 cases) and the control group (40 cases) according to the computer random number table method.The observation group was treated with leukocyte filtration transfusion, while the control group was treated with conventional blood transfusion.The indexes of blood platelet, hemoglobin and white blood cell, temperature rise during blood transfusion, fibrinogen (FIB), prothrombin time (PT), activated partial thromboplastin time (APTT) and the incidence of adverse reactions were compared between the two groups.Results The levels of blood platelet, hemoglobin and white blood cell indexes of the observation group were lower than those of the control group, the differences were statistically significant (P＜0.05).The temperature rise and during blood transfusion and FIB of the observation group were lower than those of the control group, the level of PT of the observation group was shorter than that of the control group, the level of APTT of the observation group was longer than that of the control group, the differences were statistically significant (P＜0.05).The incidence of blood transfusion adverse reactions in the observation group (5.00%) was lower than that of the control group (20.00%), and the difference was statistically significant (P＜0.05).Conclusion Leukocyte filtration transfusion technology can improve the blood quality of patients with blood transfusion, prevent the risk of adverse reactions in the process of blood transfusion, and improve the therapeutic effect of blood transfusion, which is worthy of application.
Hall S，Danby R，Osman H，et al.Transfusion in CMV seronegative T-depleted allogeneic stem cell transplant recipients with CMV-unselected blood components results in zero CMV transmissions in the era of universal leukocyte reduction：a UK dual centre experience[J].Transfus Med，2015，25（6）：418-423.
[7]
Bjursten H，Dardashti A，Bjork J，et al.Transfusion of sexmismatched and non-leukocyte-depleted red blood cells in cardiac surgery increases mortality[J].J Thoracic Cardiovasc Surg，2016，152（1）：223-232.
Sobata R，Matsumoto C，Uchida S，et al.Estimation of the infectious viral load required for transfusion-transmitted human T-lymphotropic virus type 1 infection（TT-HTLV-1）and of the effectiveness of leukocyte reduction in preventing TT-HTLV-1[J].Vox Sang，2015，109（2）：122-128.
van der Mast BJ，van den Dorpel MA，Drabbels JJM，et al.Transfusion-associated graft vs.host disease after donorspecific leukocyte transfusion before kidney transplantation[J].Clin Transplant，2003，17（5）：477-483.
京公网安备 11010502046607号